Australia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
96.20+1.05 (+1.10%)
At close: 4:00PM EST

96.20 0.00 (0.00%)
After hours: 5:45PM EST

Full screen
Trade prices are not sourced from all markets
Previous close95.15
Open95.68
Bid96.05 x 1200
Ask96.48 x 800
Day's range91.22 - 96.84
52-week range28.00 - 131.00
Volume1,684,141
Avg. volume2,828,906
Market cap23.164B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date10 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est120.01
  • China, Russia playing 'greater-than-expected' roles in global pandemic response
    Editor's pick
    Yahoo Finance

    China, Russia playing 'greater-than-expected' roles in global pandemic response

    The world grapples with the expected tug-of-war between wealthy and poorer nations over vaccine supplies, paving the way for U.S. adversaries.

  • Is BioNTech Stock a Buy?
    Motley Fool

    Is BioNTech Stock a Buy?

    When the husband-and-wife team of Dr. Ugur Sahin and Dr. Ozlem Tureci started BioNTech (NASDAQ: BNTX), they envisioned a diversified European pharmaceutical company focused on cutting-edge cancer treatments. With the authorization and distribution of Comirnaty, the COVID-19 vaccine it developed with Pfizer (NYSE: PFE), the company will have all the resources it needs to pursue its goal. A current $26 billion market capitalization is pricing in plenty of vaccine success, but BioNTech still may not be getting the credit it deserves for the other drugs in its pipeline using its revolutionary new messenger RNA (mRNA) approach.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
    Zacks

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca